Alzheimer’s disease affects over 6 million people in the United States and significantly impacts the economy, costing an estimated $321 billion in 2022, with an additional $271 billion in unpaid caregiving. Unfortunately, the number of people in the U.S. impacted by Alzheimer’s is expected to double to 12.7 million individuals by 2050, resulting in an annual cost of nearly $1 trillion.
The global Alzheimer’s therapeutics market size was valued at USD 4.05 billion in 2022 and is expected to grow to $13.7 billion by 2030.
“In Alzheimer’s, the neurons in the brain responsible for memory, language, and thinking are damaged first. Even though these symptoms are new to the affected person, the changes in the brain that cause them are believed to start at least 20 years before the symptoms manifest. With this collaboration, we aim to find early biomarkers for Alzheimer’s disease and discover new therapeutic targets to slow its progression.”
-Gaurav Chandra CEO Adnexus
Adnexus, in partnership with Khalpey AI Lab and Contenta, Ltd., Estonia, is identifying biomarkers for early onset Alzheimer’s disease. Such a discovery will lead to early diagnosis and the design of preventative therapies for effective treatment to stop the progression of Alzheimer’s at an early stage.
We will license these diagnostics and therapy resulting from this collaboration.
